<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03719417</url>
  </required_header>
  <id_info>
    <org_study_id>2011153</org_study_id>
    <nct_id>NCT03719417</nct_id>
  </id_info>
  <brief_title>A Biologic Joint Replacement Strategy for Knee Trauma and Post-Traumatic Osteoarthritis</brief_title>
  <official_title>A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Osteoarthritis (Expansion)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants will be enrolled in a prospective clinical trial to assess outcomes in 2 cohorts&#xD;
      of patients undergoing unicompartmental versus more extensive biologic OCA transplantation of&#xD;
      the knee using MOPSTM-preserved allografts (including menisci), anatomically-shaped&#xD;
      allografts, autogenous bone marrow aspirate concentrate (BMC)-treated donor bone, and&#xD;
      treatment-specific postoperative rehabilitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With IRB approval, patients will be enrolled in a prospective clinical trial to assess&#xD;
      outcomes in 2 cohorts of patients undergoing unicompartmental versus more extensive biologic&#xD;
      OCA transplantation of the knee using MOPSTM-preserved allografts (including menisci),&#xD;
      anatomically-shaped allografts, autogenous bone marrow aspirate concentrate (BMC)-treated&#xD;
      donor bone, and treatment-specific postoperative rehabilitation. Demographic and operative&#xD;
      data will be collected. Outcome assessments will include VAS pain, IKDC, SANE, Tegner and&#xD;
      PROMIS Mobility for knee at 6 months and yearly after surgery. In addition, serial limb&#xD;
      alignment measurements, ultrasonographic assessments of meniscal location and integrity,&#xD;
      quantitative MRIs for cartilage composition, and serum and urine biomarkers for treatment&#xD;
      monitoring will be performed. All complications and re-operations will be recorded. OCA&#xD;
      survival will be determined based on maintenance of acceptable levels of pain and function&#xD;
      and/or need for revision surgery or total knee arthroplasty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VAS Pain Score (Visual Analog Scale)</measure>
    <time_frame>12 Months</time_frame>
    <description>This pain score is between 0 and 10, with 0 being no pain and 10 being the worst pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Knee Documentation Committee Score (IKDC)</measure>
    <time_frame>12 Months</time_frame>
    <description>This score looks at pain and function scores. 0 is the lowest score and 100 is the highest function score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single Assessment Numeric Evaluation (SANE) score</measure>
    <time_frame>12 Months</time_frame>
    <description>This score looks at what the patient rates their knee with 100% being normal, and 0% being as far from normal as possible</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Mobility</measure>
    <time_frame>12 Months</time_frame>
    <description>This looks at mobility and function on a scale of 14.1 to 61.7 with higher scores equaling higher mobility</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <condition>Post-traumatic Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Unicompartmental Biologic Arthroplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will be receiving a unicompartmental biologic arthroplasty only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extensive Biologic Arthroplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will be receiving a unicompartmental biologic arthroplasty with at least one additional surface in another compartment being replaced concurrently.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Unicompartmental Biologic Arthroplasty</intervention_name>
    <description>Unicompartmental Biologic Arthroplasty surgery.</description>
    <arm_group_label>Unicompartmental Biologic Arthroplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extensive Biologic Arthroplasty</intervention_name>
    <description>Unicompartmental Biologic Arthroplasty surgery with an additional surface being replaced concurrently</description>
    <arm_group_label>Extensive Biologic Arthroplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Grade IV changes in the articular cartilage of the femoral condyle and tibial plateau&#xD;
             and meniscal pathology in the medial or lateral femorotibial joint (unicompartmental)&#xD;
             or unicompartmental and other femoral condyle, tibial plateau, trochlea and/or&#xD;
             patella.&#xD;
&#xD;
          -  Between the age of 18-55&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute injury to any other part of the affected lower extremity&#xD;
&#xD;
          -  Inability to comply with protocol&#xD;
&#xD;
          -  BMI greater than 40&#xD;
&#xD;
          -  The subject is either pregnant or a prisoner&#xD;
&#xD;
          -  Currently involved in worker's compensation case at the time of enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Stannard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri, Department of Orthopaedic Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Missouri Orthopaedic Institute</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2018</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>James Stannard</investigator_full_name>
    <investigator_title>Professor, Orthopedic Surgery</investigator_title>
  </responsible_party>
  <keyword>Knee Pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

